Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Mesothelioma

Clinical Trial Details

Overview

Research Study Summary

A Phase 1/Phase 2 clinical study for patients with Malignant Pleural Mesothelioma

Research Study Title

A Randomized Phase I/II Study of Standard Chemotherapy (Cisplatin and Pemetrexed) With or Without Axitinib in Patients With Malignant Mesothelioma: Interim Biopsy Analysis to Determine Efficacy

Purpose

The purpose of this study is to investigate the effects of axitinib, a potent angiogenesis inhibitor, on tissue and clinical outcome in combination with chemotherapy given to patients with mesothelioma

To Learn more
Phase

1/2

Gender

Both Male and Female

Age

18 and up

Overall Status

Recruiting

Lead Sponsor

The Netherlands Cancer Institute

Duration

16 Months

Facility Type

N/A

Eligibility

Both Male and Female ages 18 Years and up

Inclusion Criteria:

  • histologically or cytologically diagnosed malignant mesothelioma

  • age > 18 years

  • Medically suitable for limited surgical intervention (pleural biopsies or limited pleurectomy)

  • Measurable or evaluable disease is not required

  • Ability to understand the study and give signed informed consent including the approval to accept a second thoracoscopic or surgical treatment after the third course

  • No previous chemotherapy

  • Radiotherapy is allowed when this is given for palliation, the interval is > 4 weeks, not more than 1/3 of the bone marrow capacity or all tumor is within the irradiation field.

  • WHO performance status = < 2

  • Adequate organ function as evidenced by the following peripheral blood counts or serum chemistries at study entry:

Hematology:

  • ANC= > 1.5 x 109/L,

  • Platelets= > 150 x 109/L,

  • Hemoglobin = > 6,0 mmol/l

Chemistry:

  • total serum bilirubin < UNL;

  • AST and ALT= < 2.5xUNL,

  • AP < 5xUNL (unless bone metastases are present in the absence or any liver disease)

  • Serum creatinine = < 2xUNL

Exclusion Criteria:

  • Active uncontrolled infection, severe cardiac dysfunction or uncorrectable bleeding tendency

  • Previous successful pleurodesis

  • Uncontrolled hypertension

  • Symptomatic peripheral neuropathy = > grade 2 according to NCIC CTC,version 3.0

  • Presence of symptomatic CNS metastases

  • Unstable peptic ulcer, unstable diabetes mellitus or other serious disabling condition

  • Concomitant administration to any other experimental drugs under investigation

  • Impaired renal function

Site Locations (1)

Country State City Zip Facility and Contact
Netherlands Noord-Holland Amsterdam 1066 CX Antoni van Leeuwenhoekziekenhuis (NKI-AVL)
P Baas, Dr.
+31 (0)20-5122958
p.baas@nki.nl

P Baas, Dr.
Principal Investigator

Contact

P. Baas, Dr.
+31 (0)20-5122958
E-mail:

NCT ID: NCT01211275

Date Last Changed: September 28, 2010

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Some study summaries have been edited for clarity purposes to make them easier to understand. View more study details here.